Allergy Thera. Regulatory News (AGY)

For filings with the FCA include the annex

For filings with issuer exclude the annex

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Allergy Therapeutics plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

X

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

Abbott Laboratories

4. Full name of shareholder(s)  (if different from 3.):iv

CFR lnternational SpA

Yissum Holding Limited

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

20 November 2015

6. Date on which issuer notified:

20 November 2015

7. Threshold(s) that is/are crossed orreached: vi, vii

Below 41%

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ord GBP 0.01

240,584,571

240,584,571

240,584,571

40.995%

GB00B02LCQ05

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

% of voting rights xix, xx

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

240,584,571

40.995%

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

Through a series of controlled undertakings, Abbott Laboratories has an indirect holding of 99.9% of the shares in CFR Pharmaceuticals, SA.

CFR Pharmaceuticals SA's wholly owned subsidiary, CFR International SPA, holds 17.567% of the voting rights in Allergy Therapeutics plc directly and 23.428% of the voting rights in Allergy Therapeutics plc indirectly. CFR International SPA also has a 100% interest in Yissum Holding Limited, which directly holds 23.428% of shares in Allergy Therapeutics plc.

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

14. Contact name:

Des Peters

15. Contact telephone number:

+1 224-667-6545